Medicago, Glaxo To Launch Trials Of COVID-19 Vaccine Candidate In Japan

 MEDICAGO TO LAUNCH CLINICAL TRIALS FOR COVID-19 VACCINE CANDIDATE WITH GSK'S PANDEMIC ADJUVANT IN JAPAN

* MEDICAGO’S COVID-19 VACCINE CANDIDATE HAS NOW COMPLETED ENROLLMENT OF ITS PHASE 2/3 CLINICAL TRIALS

* STUDY, WITH FINAL DATA FROM GLOBAL PHASE 2/3 STUDY OF VACCINE CANDIDATE, TO BE USED TO SUPPORT APPLICATION FOR APPROVAL IN JAPAN BY MARCH OF 2022.

https://www.marketscreener.com/quote/stock/GLAXOSMITHKLINE-PLC-9590199/news/GlaxoSmithKline-Medicago-GSK-To-Launch-Trials-Of-COVID-19-Vaccine-Candidate-In-Japan-36571209/